Revance Therapeutics up on receiving billing code for dystonia injection

Revance Therapeutics

02/02/2024 13:50

** Shares of aesthetic drug maker Revance Therapeutics
 RVNC.O  rise 8.2% to $5.50 premarket
    ** Co says its injection, Daxxify, has been assigned a
permanent product-specific billing code called J-code, which
should speed up reimbursement process in an outpatient setting 
    ** The code is used by payers such as Medicare to classify
drugs that can be injected and are intended to simplify claims
submission and documentation process
    ** Daxxify was approved by the U.S. FDA as an anti-wrinkle
treatment in 2022 and for treating a neck muscle condition
called cervical dystonia in August 2023
    ** Up to last close, stock down 85% in the last 12 months



 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))